J.P. Morgan Chase & Co. is out with a research report on Alexion Pharmaceuticals ALXN and is initiating coverage with an Overweight rating and a $81 price target on shares.
In a note to clients, J.P. Morgan Chase & Co. writes, "price target of $81. Alexion has executed one the most successful launches in the orphan disease space with lead drug Soliris. Soliris is indicated for the treatment of several ultra-rare blood disorders, which if left untreated can lead to anemia, clotting and death. Following its initial approval in 2007 for a disease called PNH, Soliris has more recently garnered approval for a second condition called aHUS. Strong new patient starts, an impressive global rollout and a high price point (>$400k) have contributed to an 85% sales CAGR from launch to YE11e. Looking forward, we are bullish on Soliris growth given 1) a lot more growth left in the core PNH indication from new launch countries, 2) a larger-than-expected peak opportunity in aHUS, 3) new indications in the coming years such as kidney transplant, MG and NMO that carry a high probability of
clinical success, and 4) strong leadership, with management that has consistently “beat and raised.” On an NPV basis, we estimate that just the core PNH/aHUS indications for Soliris support our $81 target (+33% upside), but new indications could add another ~$22/share. Accordingly, we believe ALXN shares are attractive at current levels."
Shares of ALXN lost $3.19 yesterday to close at $60.87, a loss of 4.98%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in